Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial
RCT (n=853) found that secukinumab was not superior to adalimumab for ACR20 response (67% vs 62% respectively, p=0.0719), though the retention rate at 1 year was superior for secukinumab (14% vs 24% had discontinued treatment by the end of the study respectively.
Source:
The Lancet
SPS commentary:
A related commentary discusses this research, stating that this trial undoubtedly provides important new knowledge regarding the comparative efficacy and safety of two biological drugs with different mechanisms of action.